[ad_1]
Pfizer UK have confirmed the new wonderpill is being manufactured and cut the risk of hospitalisation and death by 89 percent.
Their experimental COVID-19 antiviral pill was developed to prevent the replication of SARS-CoV-2 and protect people from developing severe COVID-19.
Mr Osborn confirmed the pill could be available in the early parts of 2022.
Pfizer say the pill has shown extraordinary efficacy in the first data from a large Phase 2/3 clinical trial.
Speaking to Sky News today, Pfizer’s UK Country Manager Ben Osborn said: “We are now working at real pace with regulators around the world and in particular in the UK here with the MHRA.
“We expect the filing in the coming weeks, and subject to their approval we may see this medicine being available very early in 2022.”
The Government has already pre-ordered a quarter of a million of those treatments, and Mr Osborn said that those will be readily available.
He told Sky News: “We’ve been working with the manufacturing site at scale so that we make sure that we are ready for any forthcoming regulatory approval both here in the UK and further afield.”
While the results of the Phase 2/3 clinical trial are yet to be published in a peer reviewed journal, the new pill is an addition to a large list of incredible treatments that have been developed since outbreak of the pandemic in 2020.
Last month, a COVID-19 antiviral wonderpill was announced after pharmaceutical company Merck revealed its drug molnupiravir reduced one’s risk of hospitalization or death from COVID-19 by 50 percent.
But Pfizer’s new drug – Paxlovid – cuts the risk of hospitalisation or death by 89 percent in vulnerable adults, results from a clinical trail have indicated.
The drug should be used soon after symptoms develop in people at high risk of severe disease.
[ad_2]
